DBV Technologies S.A.
DBVTHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. At a $870.0M market cap, DBV Technologies S.A. ranks as a small-cap company within healthcare. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Market Cap
$870.0M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-27.84
EPS (TTM)
$-4.48
EPS (Fwd)
$-0.53
ROE
-142.7%
ROA
-60.6%
Cash
$174.9M
Total Debt
$7.7M
Free CF
-$111.0M
52W Change
47.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $174.9M in cash comfortably exceeding the $7.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$111.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -142.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DBVT.